[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,134
  • Shares Outstanding, K 9,941
  • Annual Sales, $ 790 K
  • Annual Income, $ 5,700 K
  • EBIT $ -84 M
  • EBITDA $ -80 M
  • 60-Month Beta 0.20
  • Price/Sales 56.45
  • Price/Cash Flow 4.12
  • Price/Book 1.26

Options Overview Details

View History
  • Implied Volatility 213.29% (+31.39%)
  • Historical Volatility 71.61%
  • IV Percentile 95%
  • IV Rank 67.73%
  • IV High 275.18% on 07/29/26
  • IV Low 83.37% on 01/21/26
  • Expected Move (DTE 4) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 85
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 3,624
  • Open Int (30-Day) 3,449
  • Expected Range 4.51 to 4.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.34
  • Number of Estimates 1
  • High Estimate $-1.34
  • Low Estimate $-1.34
  • Prior Year $0.94
  • Growth Rate Est. (year over year) -242.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.43 +1.81%
on 08/17/26
5.65 -20.18%
on 08/05/26
-0.82 (-15.38%)
since 07/17/26
3-Month
4.43 +1.81%
on 08/17/26
8.25 -45.33%
on 07/07/26
-3.13 (-40.97%)
since 05/15/26
52-Week
4.43 +1.81%
on 08/17/26
29.98 -84.96%
on 11/20/25
-12.18 (-72.98%)
since 08/15/25

Most Recent Stories

More News
Seres Therapeutics: Q2 Earnings Snapshot

Seres Therapeutics: Q2 Earnings Snapshot

MCRB : 4.51 (-0.66%)
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored trial...

MCRB : 4.51 (-0.66%)
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering...

MCRB : 4.51 (-0.66%)
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results...

MCRB : 4.51 (-0.66%)
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones Restructured lease materially reduces ongoing...

MCRB : 4.51 (-0.66%)
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright...

MCRB : 4.51 (-0.66%)
Seres Therapeutics: Q1 Earnings Snapshot

Seres Therapeutics: Q1 Earnings Snapshot

MCRB : 4.51 (-0.66%)
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biotherapeutic...

MCRB : 4.51 (-0.66%)
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers...

MCRB : 4.51 (-0.66%)
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live...

MCRB : 4.51 (-0.66%)

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 4.89
2nd Resistance Point 4.78
1st Resistance Point 4.66
Last Price 4.51
1st Support Level 4.43
2nd Support Level 4.32
3rd Support Level 4.20

See More

52-Week High 29.98
Fibonacci 61.8% 20.22
Fibonacci 50% 17.20
Fibonacci 38.2% 14.19
Last Price 4.51
52-Week Low 4.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.